JP Morgan Maintains Overweight on DexCom, Lowers Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Michael Weinstein maintains an Overweight rating on DexCom (NASDAQ:DXCM) but has lowered the price target from $160 to $100.
October 17, 2023 | 3:51 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan maintains an Overweight rating on DexCom but lowers the price target from $160 to $100.
The lowering of the price target by JP Morgan indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on DexCom's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100